FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963494698> ?p ?o ?g. }

• W1963494698 endingPage "1103" @default.
• W1963494698 startingPage "1101" @default.
• W1963494698 abstract "HomeCirculationVol. 95, No. 5What Are the Molecular Mechanisms for the Antiproliferative Effects of Nitric Oxide and cGMP in Vascular Smooth Muscle? Free AccessResearch ArticleDownload EPUBAboutView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticleDownload EPUBWhat Are the Molecular Mechanisms for the Antiproliferative Effects of Nitric Oxide and cGMP in Vascular Smooth Muscle? Ferid Murad Ferid MuradFerid Murad Search for more papers by this author Originally published4 Mar 1997https://doi.org/10.1161/01.CIR.95.5.1101Circulation. 1997;95:1101–1103Although the smooth muscle antiproliferative effects of nitric oxide and cGMP in vascular preparations have been known for several years, the precise molecular mechanisms for these effects remain unknown. Presumably these effects participate in several vascular processes, including atherogenesis, reperfusion injury, angiogenesis, inflammation, tumor growth, wound healing, and tissue grafts. A molecular understanding of these effects would no doubt provide additional therapeutic interventions for these important disorders and processes. Although the information and publications in the field of nitric oxide and cGMP have grown logarithmically in the past two decades, many important questions remain to be answered and resolved. More than 4500 publications addressing these messengers were expected in 1996, probably more than for any other research topic. Nevertheless, many important experiments remain to be done. Readers are referred to several recent reviews summarizing the effects of nitric oxide and cGMP (References 1-3). Yu and colleagues4 address the vascular smooth muscle antiproliferative effects of these messengers in this issue of Circulation.The authors find that SNP, a nitrovasodilator and nitric oxide donor or prodrug, and A-02131-1, a selective inhibitor of cGMP phosphodiesterase, decrease the proliferation of primary cultures of rat vascular smooth muscle cells that have been stimulated with one of several growth factors, such as epidermal growth factor, platelet-derived growth factor, phorbol myristate, or okadaic acid. The authors find that the effects are also mimicked by a cGMP analogue, 8-Br-cGMP, which can activate cGMP-dependent protein kinase (PKG) but is more resistant to hydrolysis by phosphodiesterase. The antiproliferative effects of SNP or 8-Br-cGMP were blocked by KT5823, presumably a selective inhibitor of cGMP-dependent protein kinase, but not by 2′,5′-dideoxyadenosine (an adenylyl cyclase inhibitor) or (R)-p-adenosine 3′,5′-cyclic monophosphothioate, a selective cAMP-dependent protein kinase inhibitor. The inhibitor of PKG, KT5823, reported by Yu et al4 is probably KT5822, which was reported by Kase et al,5 and probably represents a typographical error. This heterocyclic compound, a charged molecule derived from the culture broth of Nocardiopsis species, shows some partial selectivity of ≈15- to 33-fold for PKG inhibition compared with protein kinase A and protein kinase C when partially purified kinase preparations are used. This competitive inhibitor with respect to the substrate ATP was not tested with other kinases or purified enzymes or in intact cells and tissues to establish its cellular permeability and specificity. Its charged nature at physiological pH would suggest rather poor cellular permeability, which is unfortunately a feature of most kinase inhibitors that markedly limits their usefulness.6The authors go on to show that the antiproliferative effects of SNP and 8-Br-cGMP are associated with decreased activity of MAP kinase; MAP kinase kinase; and their regulatory proteins, RAS and Raf-1, which couple extracellular growth factor receptor–coupled tyrosine kinases to the MAP kinase cascade. The authors suggest that nitric oxide derived from SNP increases guanylyl cyclase activity and cGMP accumulation, which then activates PKG. They suggest that the activity of Raf-1 kinase is decreased as a result of cGMP-dependent phosphorylation of the protein, but they do not describe the precise mechanism or phosphorylation site.These studies are of considerable interest and may relate to other effects of nitric oxide and cGMP in other cell types and model systems. The potential interrelationships of the tyrosine kinase and serine/threonine kinase cascades offer much to one's imagination, as do the potential interrelationships of cGMP and cAMP in signal transduction.However, the study by Yu et al, although of importance, has several flaws, and additional work is certainly needed. For example, stable vascular smooth muscle cells generally are deficient in cGMP-dependent protein kinase for reasons that are unknown. Thus, primary smooth muscle cultures, which do possess cGMP-dependent protein kinase activity, are required in such studies. This invites additional problems such as cellular heterogeneity, reproducible growth conditions, and the presence of other growth factors and cytokines from the serum or contaminating cells.The concentrations of SNP used in the experiments by Yu et al are relatively high compared with the concentrations required to elevate cGMP in vascular smooth muscle and alter endogenous smooth muscle protein phosphorylation that is cGMP dependent.789 It is possible to show marked alterations in endogenous protein phosphorylation in intact smooth muscle that is cGMP-dependent with submicromolar concentrations of SNP.Although the effects of SNP and 8-Br-cGMP were concentration dependent, other nitrovasodilators and controls for 8-Br-cGMP were not tested. Some of the relatively long incubation times are also of concern considering the rapid effects of SNP on cGMP accumulation and vascular smooth muscle protein phosphorylation.789Considerable progress has been made in developing some relatively selective inhibitors of some of the protein kinases, such as protein kinase A, G, and C. However, these are generally charged organic compounds or peptides with poor permeability in intact cell experiments and are more useful in cell-free incubations on permeabilized cells. The authors do not completely address the specificity of the PKG inhibitor KLT5822 and do not provide data or reference to its permeability and efficacy with intact cells. To date, dozens of protein kinases have been described, and the development of selective inhibitors is a formidable task.With the cell-free reconstitution experiments examining PKG phosphorylation of Raf-1 (Fig 9 in the article by Yu et al), the authors use a commercial preparation of PKG and do not describe its purity and presumed lack of other kinases in their preparation. They also do not show that the Raf-1 phosphorylation in cell-free systems is indeed cGMP dependent and blocked by the PKG inhibitor KT5822. This might establish that other kinases are not participating in their effects.It has been known for more than two decades from the work of Krebs, Greengard, and others that many proteins can serve as cyclic nucleotide–dependent protein kinase substrates in cell-free preparations. This does not provide sufficient evidence that these proteins are indeed physiological substrates in intact cells. One must proceed to demonstrate phosphorylation in intact cell preparations to establish relevance and avoid artifactual phosphorylation. Optimally, one should also show the stoichiometry of phosphorylation and, if possible, the amino acid residue of importance in the protein substrate.Another commonly overlooked problem with commercially obtained biological reagents such as growth factors, cytokines, and enzymes is the possible presence of various preservatives, antibacterials, and stabilizers such as azide and fluoride. Azide can be converted to nitric oxide by catalase and other heme proteins and increases cGMP formation in intact cells as well as cell-free systems.1011121314 Furthermore, azide and nitric oxide can also increase cAMP formation from ATP catalyzed by guanylyl cyclase,1516 another reason to test the specificity of the 8-Br-cGMP effect. One should dialyze or gel filter such preparations if such additives are present to eliminate possible artifactual alterations in cGMP metabolism. Other additives and contaminants in preparations could have other effects.Although the work of Yu et al is of considerable interest and addresses a very important topic, their work invites a number of additional experiments for confirmation of the proposed cascade and greater definition of the precise mechanism of action of nitric oxide and cGMP. For example, the rather long incubation times of some experiments (1 hour and in some cases ≥1 day) do not exclude some of the effects of nitric oxide and cGMP being mediated through altered transcription or expression of some critical regulatory proteins or enzymes. Nitric oxide has been shown to decrease the transcription and expression of some proteins, such as guanylyl cyclase (A. Papapetropoulos et al, unpublished data, 1996). Demonstration of cGMP-dependent incorporation of 32P into Raf-1 in an intact cell preparation would add considerable support to their hypothesis.In spite of the incompleteness of some of the work presented and some of the deficiencies noted, the publication presents yet another important cascade system and process that may be regulated by nitric oxide and cGMP. With some additional work and confirmation, these effects could be added to the growing list of processes regulated by these messengers and signal-transduction molecules that are summarized in the Table.Selected Abbreviations and Acronyms8-Br-cGMP=8-bromo-cGMPMAP=mitogen-activated proteinPKG=protein kinase GSNP=sodium nitroprussideThe opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association. Table 1. Biological Targets or Processes Regulated by Nitric Oxide or cGMPEnzymes and macromolecules Guanylyl cyclase Cyclic nucleotide protein kinases Cyclic nucleotide phosphodiesterases Cyclooxygenase (COX 11) Heme proteins, iron centers, and thiol groups DNA modifications and repair Glutamate (NM4DA) receptor regulation* Phospholipase CProcesses Smooth, cardiac,* and skeletal* muscle relaxation Retinal phototransduction Intestinal secretion and ion transport Renal tubular-glomerular feedback* Endothelial permeability* Smooth muscle proliferation Platelet adhesion and aggregation Insulin secretion* Hormone production and secretion* Neurotransmission Long-term potentiation and memory* Transcriptional regulation* Tissue injury and inflammation Pathogen cytotoxicity Tumor cytotoxicity Calcium transport and redistributionIn some cases, the effects of nitric oxide and/or cGMP are well substantiated. However, some of the effects above can be considered interesting but preliminary and are designated with an asterisk. Please refer to some of the review articles in the “References” for additional information and mechanisms.FootnotesCorrespondence to Ferid Murad, MD, PhD, 1421 Lake Rd, Lake Forest, IL 60045. References 1 Murad F, ed. Cyclic GMP synthesis, metabolism and function. In: Advances in Pharmacology. New York, NY: Academic Press; 1994;26:1-335.Google Scholar2 Ignarro L, Murad F, eds. Nitric oxide: biochemistry, molecular biology, and therapeutic implications. In: Advances in Pharmacology. New York, NY: Academic Press; 1995;34:1-516.Google Scholar3 Murad F. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA.1996; 276:1189-1192.CrossrefMedlineGoogle Scholar4 Yu S-M, Hung L-M, Lin C-C, Ou JT, Yu J-S. cGMP-Elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation.1997; 95:1269-1277.CrossrefMedlineGoogle Scholar5 Kase H, Iwahashi K, Nakanishi S, Matsuda Y, Yamada K, Takahashi M, Murakata S, Sato A, Kaneko M. K252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide dependent protein kinase. Biochem Biophys Res Commun..1987; 142:436-440.CrossrefMedlineGoogle Scholar6 Francis SH, Corbin JD. Progress in understanding the mechanism and function of cyclic GMP-dependent protein kinase. In: Murad F, ed. Cyclic GMP synthesis, metabolism, and function. In: Advances in Pharmacology. New York, NY: Academic Press; 1994;26:115-170.Google Scholar7 Rapoport RM, Draznin MB, Murad F. Endothelium dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature.1983; 306:274-276.CrossrefMedlineGoogle Scholar8 Fiscus RR, Rapoport RM, Murad F. Endothelium-dependent and nitrovasodilator-induced activation of cyclic GMP-dependent protein kinase in rat aorta. J Cyclic Nucl Protein Phosphor Res.1983; 9:415-425.MedlineGoogle Scholar9 Rapoport RM, Murad F. Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role for cyclic GMP. J Cyclic Nucl Protein Phosphor Res.1983; 9:281-296.MedlineGoogle Scholar10 Kimura H, Mittal CK, Murad F. Activation of guanylate cyclase from rat liver and other tissues with sodium azide. J Biol Chem.1975; 250:8016-8022.CrossrefMedlineGoogle Scholar11 Kimura H, Mittal CK, Murad F. Increases in cyclic GMP levels in brain and liver with sodium azide, an activator of guanylate cyclase. Nature.1975; 257:700-702.CrossrefMedlineGoogle Scholar12 Mittal CK, Kimura H, Murad F. Requirement for a macromolecular factor for sodium azide activation of guanylate cyclase. J Cyclic Nucl Res.1975; 1:261-269.MedlineGoogle Scholar13 Katsuki S, Arnold W, Mittal CK, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucl Res.1977; 3:23-35.MedlineGoogle Scholar14 Murad F, Mittal CK, Arnold WP, Katsuki S, Kimura H. Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv Cyclic Nucl Res.1978; 9:145-158.MedlineGoogle Scholar15 Mittal CK, Murad F. Formation of adenosine 3′,5′-monophosphate by preparations of guanylate cyclase from rat liver and other tissues. J Biol Chem.1977; 252:3136-3140.CrossrefMedlineGoogle Scholar16 Mittal CK, Braughler JM, Ichihara K, Murad F. Synthesis of adenosine 3′,5′-monophosphate by guanylate cyclase: a new pathway for its formation. Biochim Biophys Acta.1979; 585:333-342.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Zuo D, Pi Q, Shi Y, Luo S and Xia Y (2021) Dihydroxyeicosatrienoic Acid, a Metabolite of Epoxyeicosatrienoic Acids Upregulates Endothelial Nitric Oxide Synthase Expression Through Transcription: Mechanism of Vascular Endothelial Function Protection, Cell Biochemistry and Biophysics, 10.1007/s12013-021-00978-x, 79:2, (289-299), Online publication date: 1-Jun-2021. Yazawa T, Sato T, Nemoto T, Nagata S, Imamichi Y, Kitano T, Sekiguchi T, Uwada J, Islam M, Mikami D, Nakajima I, Takahashi S, Khan M, Suzuki N, Umezawa A and Ida T (2021) 11-Ketotestosterone is a major androgen produced in porcine adrenal glands and testes, The Journal of Steroid Biochemistry and Molecular Biology, 10.1016/j.jsbmb.2021.105847, 210, (105847), Online publication date: 1-Jun-2021. Paskas S, Mazzon E, Basile M, Cavalli E, Al-Abed Y, He M, Rakocevic S, Nicoletti F, Mijatovic S and Maksimovic-Ivanic D (2019) Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo, Investigational New Drugs, 10.1007/s10637-019-00733-3, 37:5, (1014-1028), Online publication date: 1-Oct-2019. Restini C and Gonçalves L Nitric Oxide and Related Aspects Underlying Angina, The Open Cardiovascular Medicine Journal, 10.2174/1874192401711010033, 11:1, (33-46) Tsutsui M, Tanimoto A, Tamura M, Mukae H, Yanagihara N, Shimokawa H and Otsuji Y (2015) Significance of nitric oxide synthases: Lessons from triple nitric oxide synthases null mice, Journal of Pharmacological Sciences, 10.1016/j.jphs.2014.10.002, 127:1, (42-52), Online publication date: 1-Jan-2015. Bian K and Murad F (2014) sGC-cGMP Signaling: Target for Anticancer Therapy Advances in Fetal and Neonatal Physiology, 10.1007/978-1-4939-1031-1_2, (5-13), . Uchida T, Furuno Y, Tanimoto A, Toyohira Y, Arakaki K, Kina-Tanada M, Kubota H, Sakanashi M, Matsuzaki T, Noguchi K, Nakasone J, Igarashi T, Ueno S, Matsushita M, Ishiuchi S, Masuzaki H, Ohya Y, Yanagihara N, Shimokawa H, Otsuji Y, Tamura M and Tsutsui M (2014) Development of an experimentally useful model of acute myocardial infarction: 2/3 nephrectomized triple nitric oxide synthases-deficient mouse, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2014.09.021, 77, (29-41), Online publication date: 1-Dec-2014. SHIBATA K, SHIMOKAWA H, YANAGIHARA N, OTSUJI Y and TSUTSUI M (2013) Nitric Oxide Synthases and Heart Failure ― Lessons from Genetically Manipulated Mice, Journal of UOEH, 10.7888/juoeh.35.147, 35:2, (147-158), . Al Gadban M, German J, Truman J, Soodavar F, Riemer E, Twal W, Smith K, Heller D, Hofbauer A, Oates J and Hammad S (2012) Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus, Cellular Immunology, 10.1016/j.cellimm.2012.03.007, 276:1-2, (42-51), Online publication date: 1-Mar-2012. Morisada N, Nomura M, Nishii H, Furuno Y, Sakanashi M, Sabanai K, Toyohira Y, Ueno S, Watanabe S, Tamura M, Matsumoto T, Tanimoto A, Sasaguri Y, Shimokawa H, Kusuhara K, Yanagihara N, Shirahata A and Tsutsui M (2010) Complete Disruption of All Nitric Oxide Synthase Genes Causes Markedly Accelerated Renal Lesion Formation Following Unilateral Ureteral Obstruction in Mice In Vivo, Journal of Pharmacological Sciences, 10.1254/jphs.10143FP, 114:4, (379-389), . Tsutsui M, Shimokawa H, Otsuji Y and Yanagihara N (2010) Pathophysiological relevance of NO signaling in the cardiovascular system: Novel insight from mice lacking all NO synthases, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2010.08.010, 128:3, (499-508), Online publication date: 1-Dec-2010. Shimokawa H and Tsutsui M (2010) Nitric oxide synthases in the pathogenesis of cardiovascular disease, Pflügers Archiv - European Journal of Physiology, 10.1007/s00424-010-0796-2, 459:6, (959-967), Online publication date: 1-May-2010. Yatera Y, Shibata K, Furuno Y, Sabanai K, Morisada N, Nakata S, Morishita T, Toyohira Y, Wang K, Tanimoto A, Sasaguri Y, Tasaki H, Nakashima Y, Shimokawa H, Yanagihara N, Otsuji Y and Tsutsui M (2010) Severe dyslipidaemia, atherosclerosis, and sudden cardiac death in mice lacking all NO synthases fed a high-fat diet, Cardiovascular Research, 10.1093/cvr/cvq092, 87:4, (675-682), Online publication date: 1-Sep-2010., Online publication date: 1-Sep-2010. Kapadia M, Eng J, Jiang Q, Stoyanovsky D and Kibbe M (2009) Nitric oxide regulates the 26S proteasome in vascular smooth muscle cells, Nitric Oxide, 10.1016/j.niox.2009.02.005, 20:4, (279-288), Online publication date: 1-Jun-2009. Tsutsui M, Nakata S, Shimokawa H, Otsuji Y and Yanagihara N (2008) Spontaneous Myocardial Infarction and Nitric Oxide Synthase, Trends in Cardiovascular Medicine, 10.1016/j.tcm.2008.12.002, 18:8, (275-279), Online publication date: 1-Nov-2008. Sabanai K, Tsutsui M, Sakai A, Hirasawa H, Tanaka S, Nakamura E, Tanimoto A, Sasaguri Y, Ito M, Shimokawa H, Nakamura T and Yanagihara N (2008) Genetic Disruption of All NO Synthase Isoforms Enhances BMD and Bone Turnover in Mice In Vivo: Involvement of the Renin-Angiotensin System, Journal of Bone and Mineral Research, 10.1359/jbmr.080107, 23:5, (633-643) Desmard M, Boczkowski J, Poderoso J and Motterlini R (2007) Mitochondrial and Cellular Heme-Dependent Proteins as Targets for the Bioactive Function of the Heme Oxygenase/Carbon Monoxide System, Antioxidants & Redox Signaling, 10.1089/ars.2007.1803, 9:12, (2139-2156), Online publication date: 1-Dec-2007. TSUTSUI M, SHIMOKAWA H, MORISHITA T, NAKATA S, SABANAI K, NAKASHIMA Y and YANAGIHARA N (2007) Development of Genetically Engineered Mice Lacking All Three Nitric Oxide Synthase IsoformsNO合成酵素完全欠損マウスの開発, YAKUGAKU ZASSHI, 10.1248/yakushi.127.1347, 127:9, (1347-1355), Online publication date: 1-Sep-2007. Tsutsui M, Shimokawa H, Morishita T, Nakashima Y and Yanagihara N (2006) Development of Genetically Engineered Mice Lacking All Three Nitric Oxide Synthases, Journal of Pharmacological Sciences, 10.1254/jphs.CPJ06015X, 102:2, (147-154), . Morishita T, Tsutsui M, Shimokawa H, Sabanai K, Tasaki H, Suda O, Nakata S, Tanimoto A, Wang K, Ueta Y, Sasaguri Y, Nakashima Y and Yanagihara N (2005) Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms, Proceedings of the National Academy of Sciences, 10.1073/pnas.0502236102, 102:30, (10616-10621), Online publication date: 26-Jul-2005. Fung E, Fiscus R, Yim A, Angelini G and Arifi A (2005) The Potential Use of Type-5 Phosphodiesterase Inhibitors in Coronary Artery Bypass Graft Surgery, Chest, 10.1378/chest.128.4.3065, 128:4, (3065-3073), Online publication date: 1-Oct-2005. Pradhan L, Dabisch P, Liles J, Murthy S, Baber S, Simpson S, Agrawal K and Kadowitz P (2005) Effect of binge cocaine treatment on hindlimb vascular function, Journal of Applied Toxicology, 10.1002/jat.1083, 25:6, (479-490), Online publication date: 1-Nov-2005. Browner N, Dey N, Bloch K and Lincoln T (2004) Regulation of cGMP-dependent Protein Kinase Expression by Soluble Guanylyl Cyclase in Vascular Smooth Muscle Cells, Journal of Biological Chemistry, 10.1074/jbc.M408518200, 279:45, (46631-46636), Online publication date: 1-Nov-2004. Cornwell T, Ceaser E, Li J, Marrs K, Darley-Usmar V and Patel R (2003) S -nitrosothiols inhibit uterine smooth muscle cell proliferation independent of metabolism to NO and cGMP formation , American Journal of Physiology-Cell Physiology, 10.1152/ajpcell.00268.2002, 284:6, (C1516-C1524), Online publication date: 1-Jun-2003. Feng X, Guo Z, Nourbakhsh M, Hauser H, Ganster R, Shao L and Geller D (2002) Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter: The role of NF-κB-repressing factor (NRF) in basal repression of the hiNOS gene, Proceedings of the National Academy of Sciences, 10.1073/pnas.212306199, 99:22, (14212-14217), Online publication date: 29-Oct-2002. Chen H, Jiang W and Tzeng C (2001) Nitric oxide as a regulator in preimplantation embryo development and apoptosis, Fertility and Sterility, 10.1016/S0015-0282(01)01780-0, 75:6, (1163-1171), Online publication date: 1-Jun-2001. Buergler J, Tio F, Schulz D, Khan M, Mazur W, French B, Raizner A and Ali N (2000) Use of nitric-oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs, Coronary Artery Disease, 10.1097/00019501-200006000-00009, 11:4, (351-357), Online publication date: 1-Jun-2000. Kastrati A, Dirschinger J and Schömig A (2000) Genetic risk factors and restenosis after percutaneous coronary interventionsGenetische Risikofaktoren und Restenose nach perkutanen Koronarinterventionen, Herz, 10.1007/BF03044122, 25:1, (34-46), Online publication date: 1-Feb-2000. McCarty M (1999) Endothelial membrane potential regulates production of both nitric oxide and superoxide – a fundamental determinant of vascular health, Medical Hypotheses, 10.1054/mehy.1998.0758, 53:4, (277-289), Online publication date: 1-Oct-1999. Lorell B (1999) Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and disease, The American Journal of Cardiology, 10.1016/S0002-9149(99)00258-1, 83:12, (48-52), Online publication date: 1-Jun-1999. Suhasini M, Li H, Lohmann S, Boss G and Pilz R (1998) Cyclic-GMP-Dependent Protein Kinase Inhibits the Ras/Mitogen-Activated Protein Kinase Pathway, Molecular and Cellular Biology, 10.1128/MCB.18.12.6983, 18:12, (6983-6994), Online publication date: 1-Dec-1998. Mönks , Lange , Silber , Markert , Walter and Nehls (2001) Expression of cGMP-dependent protein kinase I and its substrate VASP in neointimal cells of the injured rat carotid artery, European Journal of Clinical Investigation, 10.1046/j.1365-2362.1998.00308.x, 28:5, (416-423), Online publication date: 1-May-1998. Fang S, Sharma R and Bhalla R (1997) Endothelial Nitric Oxide Synthase Gene Transfer Inhibits Platelet-Derived Growth Factor-BB Stimulated Focal Adhesion Kinase and Paxillin Phosphorylation in Vascular Smooth Muscle Cells, Biochemical and Biophysical Research Communications, 10.1006/bbrc.1997.7035, 236:3, (706-711), Online publication date: 1-Jul-1997. Sagredo A, del Campo L, Martorell A, Navarro R, Martín M, Blanco-Rivero J, Ferrer M and Schlossmann J (2013) Ovariectomy Increases the Participation of Hyperpolarizing Mechanisms in the Relaxation of Rat Aorta, PLoS ONE, 10.1371/journal.pone.0073474, 8:9, (e73474) Berkban T, Boonprom P, Bunbupha S, Welbat J, Kukongviriyapan U, Kukongviriyapan V, Pakdeechote P and Prachaney P (2015) Ellagic Acid Prevents L-NAME-Induced Hypertension via Restoration of eNOS and p47phox Expression in Rats, Nutrients, 10.3390/nu7075222, 7:7, (5265-5280) Harden O and Hammad S (2020) Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus, Frontiers in Immunology, 10.3389/fimmu.2020.586737, 11 March 4, 1997Vol 95, Issue 5 Advertisement Article InformationMetrics Copyright © 1997 by American Heart Associationhttps://doi.org/10.1161/01.CIR.95.5.1101 Originally publishedMarch 4, 1997 Keywordsmolecular biologyEditorialsmuscle, smooth Advertisement" @default.
• W1963494698 created "2016-06-24" @default.
• W1963494698 creator A5066062695 @default.
• W1963494698 date "1997-03-04" @default.
• W1963494698 modified "2023-10-17" @default.
• W1963494698 title "What Are the Molecular Mechanisms for the Antiproliferative Effects of Nitric Oxide and cGMP in Vascular Smooth Muscle?" @default.
• W1963494698 cites W1430426163 @default.
• W1963494698 cites W1487299102 @default.
• W1963494698 cites W2010368204 @default.
• W1963494698 cites W2042915038 @default.
• W1963494698 cites W2057433961 @default.
• W1963494698 cites W2068669272 @default.
• W1963494698 cites W2085093642 @default.
• W1963494698 cites W75180347 @default.
• W1963494698 doi "https://doi.org/10.1161/01.cir.95.5.1101" @default.
• W1963494698 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9054833" @default.
• W1963494698 hasPublicationYear "1997" @default.
• W1963494698 type Work @default.
• W1963494698 sameAs 1963494698 @default.
• W1963494698 citedByCount "46" @default.
• W1963494698 countsByYear W19634946982012 @default.
• W1963494698 countsByYear W19634946982013 @default.
• W1963494698 countsByYear W19634946982014 @default.
• W1963494698 countsByYear W19634946982015 @default.
• W1963494698 countsByYear W19634946982016 @default.
• W1963494698 countsByYear W19634946982017 @default.
• W1963494698 countsByYear W19634946982019 @default.
• W1963494698 countsByYear W19634946982020 @default.
• W1963494698 countsByYear W19634946982021 @default.
• W1963494698 countsByYear W19634946982022 @default.
• W1963494698 crossrefType "journal-article" @default.
• W1963494698 hasAuthorship W1963494698A5066062695 @default.
• W1963494698 hasConcept C126322002 @default.
• W1963494698 hasConcept C164705383 @default.
• W1963494698 hasConcept C2779395532 @default.
• W1963494698 hasConcept C2992686903 @default.
• W1963494698 hasConcept C519581460 @default.
• W1963494698 hasConcept C71924100 @default.
• W1963494698 hasConcept C98274493 @default.
• W1963494698 hasConceptScore W1963494698C126322002 @default.
• W1963494698 hasConceptScore W1963494698C164705383 @default.
• W1963494698 hasConceptScore W1963494698C2779395532 @default.
• W1963494698 hasConceptScore W1963494698C2992686903 @default.
• W1963494698 hasConceptScore W1963494698C519581460 @default.
• W1963494698 hasConceptScore W1963494698C71924100 @default.
• W1963494698 hasConceptScore W1963494698C98274493 @default.
• W1963494698 hasIssue "5" @default.
• W1963494698 hasLocation W19634946981 @default.
• W1963494698 hasLocation W19634946982 @default.
• W1963494698 hasOpenAccess W1963494698 @default.
• W1963494698 hasPrimaryLocation W19634946981 @default.
• W1963494698 hasRelatedWork W1531601525 @default.
• W1963494698 hasRelatedWork W266669417 @default.
• W1963494698 hasRelatedWork W2758277628 @default.
• W1963494698 hasRelatedWork W2935909890 @default.
• W1963494698 hasRelatedWork W2948807893 @default.
• W1963494698 hasRelatedWork W3173606202 @default.
• W1963494698 hasRelatedWork W3183948672 @default.
• W1963494698 hasRelatedWork W4387497383 @default.
• W1963494698 hasRelatedWork W2778153218 @default.
• W1963494698 hasRelatedWork W3110381201 @default.
• W1963494698 hasVolume "95" @default.
• W1963494698 isParatext "false" @default.
• W1963494698 isRetracted "false" @default.
• W1963494698 magId "1963494698" @default.
• W1963494698 workType "article" @default.